




Overview

Maravai is a leading life sciences company that provides critical products to enable the development of drug therapies, diagnostics, and novel vaccines and that supports research on human diseases. Its customers include the top 20 global biopharmaceutical companies by R&D spend. Maravai's market leading position stems from its proprietary technologies and products produced under exacting quality standards. The Company is well-positioned to serve increasing customer demand, which is being driven by the forecasted, rapid growth in the RNA therapeutics and vaccines pipelines as well as in cell and gene therapy. Maravai is led by a proven management team with significant life sciences expertise.

Strong technology foundation enabling solutions for next-generation therapeutic modalities and technologies

We provide enabling solutions from discovery through to commercialization



1. AAE = Antibody Affinity Extraction™


Targeting attractive and rapidly growing end markets

Pipelines of all novel modalities are increasing significantly

Product Pipeline Growth¹ (%)

2019–2021

Key Development Areas



1. Source – Informa report

2. Includes products, use cases and customer types relevant to Maravai

Strong financial profile and organic growth

Strong revenue growth profile generating robust cash flows



3. Cash and long-term debt as of 9/30/21

4. Non-GAAP Reconciliations, provided by Maravai

5. Free cash flow defined as Adjusted EBITDA less capex

Well positioned to deploy our balance sheet and invest in the business

- Strategic M&A with companies meeting our profile supports long-term growth
 - High technology, high quality, founder-based businesses
 - Blue chip, “sticky customer base”
 - Attractive revenue growth and EBITDA margin profile
 - Strong market growth and synergies with existing businesses
 - Immediate ability to integrate into operations
 - Example: recent MyChem acquisition is synergistic with Nucleic Acid Production pipeline and growth plans
- Facility expansions and efficiencies support near- and mid-term growth plans
- Operational investments strengthen our business while supporting our core values
 - Supply chain
 - Human capital management
 - Environmental initiatives
 - Read more on <https://investors.maravai.com/esg>

Maravai LifeSciences

10770 Wateridge Circle, Suite 110
San Diego, CA 92121
www.maravai.com

Deb Hart

Head of Investor Relations
Direct: 858-988-5917
debra.hart@maravai.com

Financial flexibility allows us to make organic and inorganic investments

Organic Investments

- ✓ Technology innovation
- ✓ Process engineering
- ✓ GMP capacity
- ✓ Portfolio expansion

Inorganic Investments

- ✓ Complementary or synergistic capabilities
- ✓ Vertical integration of supply chain
- ✓ International expansion
- ✓ Enhance quality systems

Investing in our opportunities



We are playing in the right target markets with strong leadership positions and building our portfolio in high-value areas.



There is a significant opportunity for Maravai to emerge as a leading, critical supplier and solutions provider in the life sciences industry.



We are building a strong foundation for long-term, sustainable growth by investing in our core capabilities, operations, manufacturing and people.